MedPath
EMA Product

Ristaben

Product approved by European Medicines Agency (EU)

Basic Information

Ristaben

Regulatory Information

EMEA/H/C/001234

Authorised

March 15, 2010

December 17, 2009

28

July 25, 2024

Company Information

the netherlands

Waarderweg 39 2031 BN Haarlem

Merck Sharp & Dohme BV

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication For adult patients with type-2 diabetes mellitus, Ristaben is indicated to improve glycaemic control: - as monotherapy: - in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance; - as dual oral therapy in combination with: - metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control; - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance; - a peroxisome proliferator-activated-receptor-gamma (PPAR?) agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control; - as triple oral therapy in combination with: - a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control; - a PPAR? agonist and metformin when use of a PPAR? agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. Ristaben is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Overview Summary

This is a summary of the European public assessment report (EPAR) for Ristaben. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ristaben.

© Copyright 2025. All Rights Reserved by MedPath